Pfizer awarded $4.85B Army modification contract for Paxlovid

 Pfizer Inc., New York, New York, was awarded a $4,852,867,500 modification (P00004) to contract W58P05-22-C-0001 for the oral therapeutic PAXLOVID. Work will be performed in New York, New York, with an estimated completion date of March 31, 2023. Fiscal 2022 American Rescue Plan Act funds; Coronavirus Aid, Relief, and Economic Security Act funds; Coronavirus Preparedness Response and Relief Supplemental Appropriations Act funds; and Coronavirus Response and Relief Supplemental Appropriations Act funds in the amount of $4,852,867,500 were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity.

https://www.defense.gov/News/Contracts/Contract/Article/3151585//